DEFA14A ·Filed Apr 29, 2026

MDXG

MIMEDX GROUP, INC.
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago SEC0001376339-26-000037
Proxy solicitation materials
Actionable Insight • Neutral

Monitor for the definitive proxy statement (DEF 14A) and any disclosure of shareholder proposals or voting items. The recent cost reduction program may be a precursor to activist engagement or management restructuring proposals.

DirectionNeutral
Confidencelow
Horizonweeks
Final — all horizons settled through T+60d
MDXG ▲ +26.79% at T+60d
NEUTRAL call ✓ call won +26.79% · α vs SPY +23.68% · entry $3.36 → $4.26
Entry anchored
Apr 29, 03:59 PM ET
via exchange tick
T+1d
0.00%
call 0.00% · α -0.22%
$3.36
settled 5mo ago
T+5d
+8.93%
call +8.93% · α +7.20%
$3.66
settled 5mo ago
T+20d
+9.23%
call +9.23% · α +4.26%
$3.67
settled 4mo ago
T+60d
+26.79%
call +26.79% · α +23.68%
$4.26
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

MiMedx Group filed a DEFA14A (additional definitive proxy soliciting materials). The substantive content of the filing is unavailable as only cover page and encoded graphic images were provided. The filing follows an April 16 8-K announcing a cost reduction initiative expected to generate $40 million in annualized savings, including elimination of the COO role. Without readable proxy content, the specific proposals or solicitation matters cannot be determined.

Key Facts

  • Filing type: DEFA14A (additional definitive proxy soliciting materials)
  • Filed April 29, 2026, following an April 16, 2026 8-K announcing cost reduction and executive changes
  • Prior 8-K projected $40 million in annualized savings and a one-time $4 million restructuring charge
  • Proxy statement content (definitive additional materials) not available in parsed text form

Financial Impact

Not specified

Risk Factors

  • Potential activist campaign or shareholder vote outcome uncertainty
  • Restructuring may impact near-term revenue growth

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001376339-26-000037
Document: 0001376339-26-000037-index-headers.html0001376339-26-000037
Document: 0001376339-26-000037-index.html0001376339-26-000037
Document: 0001376339-26-000037.txt0001376339-26-000037
4 reports for MDXG
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for MDXG — sortable, filterable
TypeNow
Jun 2, 2026
17w ago
Court Ruling
BULLISH ★ 5/10
$3.57 $4.42▲ +23.81%▲ +22.69%$4.59 (+28.57%)
Apr 29, 2026
22w ago
DEFA14A
NEUTRAL ★ 3/10
$3.36 $4.26▲ +26.79%▲ +23.68%$4.59 (+36.61%)
Apr 22, 2026
23w ago
Press Release
NEUTRAL ★ 3/10
$3.31 $4.30▲ +29.91%▲ +25.13%$4.59 (+38.67%)
Apr 16, 2026
24w ago
8-K
BEARISH ★ 7/10
$3.43 $4.08▼ −18.95%▼ −11.90%$4.59 (−33.82%)
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (65h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access